Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug for people with multiple myeloma that has come back or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My multiple myeloma has spread to my brain and is causing symptoms.I had a stem cell transplant using my own cells less than 3 months ago.I had a stem cell transplant less than a year ago.I am currently receiving treatment for another type of cancer.My multiple myeloma has come back and is not responding to treatment.I am fully active or can carry out light work.You must have a disease that can be measured by a special laboratory.
- Group 1: Administration of CC-93269
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary goals of this trial to accomplish?
"According to the trial sponsor, Celgene, this medical research will assess its primary outcome of Dose Limiting Toxicity (DLT) over a span of up to 60 months. Additionally, secondary outcomes such as Overall Response Rate (ORR), Progression Free Survival and Pharmacokinetics - CL are also being monitored. Respectively these metrics measure International Myeloma Working Group (IMWG) response criteria achievement, time until progressive disease or death from any cause occurs after first drug dose administration and apparent total body clearance respectively."
Are there various healthcare centers conducting this research experiment in the US?
"This clinical trial has 10 enrolment sites, with the University Of Alabama At Birmingham in Birmingham, Yale Cancer Center in New Haven and University of Alabama at Birmingham in Seattle being amongst them. Additionally, there are 7 other locations available for patient participation."
Are investigators currently recruiting participants for this research experiment?
"According to clinicaltrials.gov, this particular medical experiment has ceased recruiting patients since November 8th 2022 and was initially posted on April 3rd 2018. However, there are still 807 other trials actively searching for participants."
Has CC-93269 been given the endorsement of the FDA?
"The safety of CC-93269 is somewhat uncertain due to the rudimentary nature of this Phase 1 study, and it was consequently rated a 1 out of 3 by our Power team."
Share this study with friends
Copy Link
Messenger